TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17990475
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care via intermittent suction
Study: 15847101
Drug: Artrofoon (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artrofoon (8 tablets daily, n = 30)
Study: 15847101
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg daily, n = 30)
Study: 15847101
Drug: Artrofoon (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artrofoon (4 tablets daily)
Study: 9785074
Drug: Org 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9487 1 mg kg‐1
Study: 9785074
Drug: Org 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9487 2 mg kg‐1
Study: 9785074
Drug: Org 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9487 3 mg kg‐1
Study: 364364
Drug: Dipyridamole 225
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole 225 mg/day and acetylsalicylic acid 1 gm/day
Study: 28083842
Drug: VPZ 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPZ 20 mg once daily for 3 weeks
Study: 28083842
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg once daily for 3 weeks
Study: 19445938
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance measured by HOMA2-IR
Study: 16768836
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg supplemental Zn per day
Study: 16768836
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg supplemental Zn per day
Study: 16768836
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg supplemental Zn per day (placebo)
Study: 14695850
Drug: Purine analogs
Normalized name: Purine analogs, antimetabolites antineoplastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purine analogs alone or in combination with alkylating agents and monoclonal antibodies
Study: 14695850
Drug: Alkylating agent-based
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agent-based therapy
Study: 11323555
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg‐1 of body mass)
Study: 9460568
Drug: Nurse Specialist
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse Specialist Anticoagulant Service (NSAS)
Study: 9460568
Drug: Consultant Anticoagulant
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultant Anticoagulant Service (CAS)
Study: 7943793
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg i.v.)
Study: 7943793
Drug: Ketamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.1 mg/kg i.v.)
Study: 7943793
Drug: Adenosine +
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine + Morphine
Study: 3145269
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents (general)
Study: 31980499
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg and 1000 mg)
Study: 17145651
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoflavones, lignans and Cimicifuga racemosa (group A, n = 40)
Study: 17145651
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (group B, n = 40)
Study: 11760165
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment (3 million units daily for the first 14 days, then 3 times per week)
Study: 11760165
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (3 million units 3 times per week throughout)
Study: 9268221
Drug: Tiqueside (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiqueside (1, 2, and 3 g daily, b.i.d.)
Study: 9268221
Drug: Tiqueside (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiqueside (2 or 4 g/day, once daily)
Study: 8359182
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) 0.4 mg
Study: 8359182
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) 0.8 mg
Study: 3458681
Drug: Gel alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel alone
Study: 21988715
Drug: Acetil salicylic
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetil salicylic acid (ASA) 100 mg daily until third month of pregnancy
Study: 21988715
Drug: Low molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular-weight heparin (LMWH) - enoxaparine 40 mg daily until third month of pregnancy
Study: 21988715
Drug: ASA 100
Normalized name: ASA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 100 mg plus LMWH 40 mg daily until third month of pregnancy
Study: 21988715
Drug: ASA 100
Normalized name: ASA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 100 mg daily until third month of pregnancy
Study: 10776982
Drug: GRADEX (granisetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRADEX (granisetron 3 mg i.v. + dexamethasone 20 mg i.v.)
Study: 10776982
Drug: TRODEX (tropisetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRODEX (tropisetron 5 mg i.v. + dexamethasone 20 mg i.v.)
Study: 10776982
Drug: ONDEX (ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONDEX (ondansetron 8 mg i.v. + dexamethasone 20 mg i.v. followed by ondansetron 8 mg p.o. x 2)
Study: 4016545
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin treatment (5000 units twice daily subcutaneously)
Study: 4016545
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin treatment supplemented with graded compression stockings
Study: 17687276
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg single-dose intravenous parecoxib
Study: 12650956
Drug: Fluvoxamine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 300 mg/day
Study: 10319772
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with meperidine
Study: 24894079
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) with innovative negative pressure device (NPD)
Study: 16162997
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg BID for 7 days
Study: 16162997
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg QD for 7 days
Study: 10966246
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg bolus plus 2 microg/kg/hr infusion for 4 hours)
Study: 3937501
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule of nifedipine
Study: 3937501
Drug: 2 capsules
Normalized name: Xymogen Berberine With Insea2 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules (20 mg) of nifedipine
Study: 3937501
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet of nifedipine
Study: 3937501
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tablet of nifedipine
Study: 3937501
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tablet of nifedipine
Study: 3937501
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 20 mg daily of the tablet form of nifedipine
Study: 3937501
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 40 mg of the nifedipine tablets
Study: 30006694
Drug: Centhaquin 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centhaquin 0.015 mg/kg
Study: 26092233
Drug: pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegfilgrastim 6 mg
Study: 15705376
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 1.2 g/d with clomiphene citrate (CC) 100 mg/d for 5 days
Study: 15705376
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with clomiphene citrate (CC) 100 mg/d for 5 days
Study: 12849761
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication (L-Dopa), specific dosage and duration not mentioned
Study: 12849761
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of dopaminergic medication (off medication)
Study: 10533471
Drug: Formestane (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane (250 mg intramuscularly every 2 weeks)
Study: 8901143
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of chlorprothixene (100 mg)
Study: 8901143
Drug: Oral aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aqueous solution of chlorprothixene (100 mg)
Study: 8901143
Drug: Coated tablet
Normalized name: COATED TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablet of chlorprothixene (100 mg)
Study: 8901143
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of chlorprothixene (100 mg)
Study: 21840651
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg carisoprodol
Study: 21840651
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg carisoprodol followed by 10 mg oxycodone after 60 min
Study: 19703819
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) plus atorvastatin (10 mg) daily for 6 months
Study: 19703819
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg) plus atorvastatin (10 mg) daily for 6 months
Study: 9042316
Drug: Methioninase (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methioninase (5,000 units, 2-hour infusion)
Study: 9042316
Drug: Methioninase (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methioninase (10,000 units, 2-hour infusion)
Study: 9042316
Drug: Methioninase (20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methioninase (20,000 units, 10-hour infusion)
Study: 6147066
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal therapy (standardized information, self-exposure instructions, and anxiolytic medication)
Study: 21470906
Drug: Interactive e-drug
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interactive e-drug calculations package
Study: 10685748
Drug: Braintree polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braintree polyethylene glycol (PEG) laxative 17 g
Study: 9157586
Drug: rHDL (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHDL (40 mg/kg, given as a 4 h infusion starting 3.5 h prior to LPS injection)
Study: 3453715
Drug: Ketotifen 2
Normalized name: ketotifen 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2 mg/d with desensitization
Study: 3453715
Drug: Specific hyposensitization
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific hyposensitization treatment
Study: 24047189
Drug: Echocardiographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiographically guided ibuprofen treatment
Study: 24047189
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen treatment
Study: 22486722
Drug: BioCell Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioCell Collagen (BCC) 2 g
Study: 20507953
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive renal replacement therapy
Study: 10480205
Drug: High-dose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (200 units Botox per leg)
Study: 10480205
Drug: Low-dose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (100 units Botox per leg)
Study: 8911559
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg paroxetine daily
Study: 386715
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg imipramine daily
Study: 7362377
Drug: Meperidine hydrochloride
Normalized name: Meperidine Hydrochloride
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine hydrochloride (45 mg)
Study: 17613971
Drug: Outpatient Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient Treatment (OP)
Study: 15462690
Drug: rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 5 mg and 10 mg
Study: 9382964
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.1 IU x kg(‐1) x day(‐1)) for 4 days
Study: 9382964
Drug: Glucocorticoid (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (50 mg/d) for 4 days
Study: 9382964
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone plus glucocorticoid
Study: 9382964
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline injections for 4 days)
Study: 8390369
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bisoprolol p.o. (pretreatment)
Study: 8390369
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg celiprolol p.o.
Study: 3548809
Drug: Hypo-osmolar formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar formulation using polyvinylpyrrolidone and hydroxyethyl cellulose
Study: 3548809
Drug: Hypo-osmolar preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar preparations of BJ6
Study: 29986448
Drug: Shooters with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shooters with blood lead levels (BLL) ≥ 5 µg/dL
Study: 24428468
Drug: ABT-450/r (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450/r (150 mg of ABT-450 and 100 mg of ritonavir) plus ribavirin for 8 weeks
Study: 24428468
Drug: ABT-450/r (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450/r (150 mg of ABT-450 and 100 mg of ritonavir) plus ribavirin for 12 weeks
Study: 24428468
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment subgroups (various regimens of direct-acting antiviral agents and ribavirin)
Study: 22774206
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg daily by mouth
Study: 17712755
Drug: Isoniazid monotherapy
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid monotherapy for 9 months (group A)
Study: 16371678
Drug: Methylphenidate (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (usual medication)
Study: 31769998
Drug: Drug repurposing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug repurposing candidates identified through integration of pharmacodynamic and marketing variables from DrugBank and genomic data from BioVU.
Study: 25363555
Drug: First-line therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line therapy (PPI-based triple therapy for seven days)
Study: 25363555
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy (moxifloxacin-based triple therapy or bismuth-based quadruple therapy)
Study: 25363555
Drug: Third-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line therapy (unused MA or QUAD)
Study: 19738139
Drug: Empirical antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antiarrhythmic drug (AAD) therapy for 6 weeks after AF ablation
Study: 19738139
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic therapy (no-AAD group)
Study: 19738139
Drug: Empirical antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antiarrhythmic drug (AAD) therapy
Study: 17557041
Drug: High-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose proton pump inhibitor (PPI) therapy
Study: 7917776
Drug: Transdermal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal morphine (10 mg)
Study: 7917776
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (10 mg over 20 min)
Study: 3045441
Drug: Lithium (Li)
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (Li) therapy
Study: 23085153
Drug: Dutasteride 0.5mg
Normalized name: DUTASTERIDE 0.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5mg daily for six months
Study: 12784273
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of placebo injected into the parotids and submandibular glands
Study: 11171715
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg/d for 3 days)
Study: 1554077
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment of the anterior cruciate ligament
Study: 4019257
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ascorbic acid twice a day for 60 days
Study: 23697585
Drug: LCn‐3PUFA (fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCn‐3PUFA (fish oil) 6 × 1 g capsules/d
Study: 23697585
Drug: Placebo (monounsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (monounsaturated oil) 6 × 1 g capsules/d
Study: 19489494
Drug: Surrounded needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrounded needling therapy
Study: 19489494
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Indomethacin and Allopurinol)
Study: 17272406
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (8-10 days)
Study: 17272406
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (8-10 days)
Study: 17272406
Drug: Episodic hypoxia
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic hypoxia (after treatment with testosterone or placebo)
Study: 1679645
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flumazenil
Study: 1679645
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of flumazenil (2-5 mg)
Study: 7041850
Drug: Simple exercise
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple exercise therapy
Study: 6691783
Drug: CT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT plus pharmacotherapy
Study: 28333879
Drug: Sustained Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Group (monthly IAI for 3 months, then every 2 months for 12 months)
Study: 28333879
Drug: PRN Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN Group (1 IAI at randomization, then monthly PRN IAI for 12 months)
Study: 24161334
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for both TI and CLI patients
Study: 18545057
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/day, intravenous)
Study: 12840614
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment procedures including epidural steroids, trigger point injections, and cognitive-behaviorally oriented psychoeducational groups
Study: 11142163
Drug: Continuous intraportal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraportal 5-FU infusion
Study: 11142163
Drug: UFT/LV (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (oral chemotherapy)
Study: 8864039
Drug: Females using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Females using oral contraceptives
Study: 6361628
Drug: Nabumetone, 500
Normalized name: Nabumetone, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone, 500 mg two nocte
Study: 6361628
Drug: Naproxen, 250
Normalized name: Naproxen, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 250 mg two nocte and one mane
Study: 27596132
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl 2 g/day
Study: 7560220
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral hygiene alone
Study: 9408065
Drug: Picotamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (300 mg b.i.d.)
Study: 1834396
Drug: Low-dosage aspirin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage aspirin (300 mg/die)
Study: 7127989
Drug: Syringe for
Normalized name: Cimzia 200mg/mL Prefilled Syringe for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe for medication delivery